Astrazeneca beats forecasts due to strong drug sales in lockdown July 30, 2020 Pharmaceuticals giant Astrazeneca this morning reported better than expected second-quarter sales and profits for the second quarter due to strong sales during the coronavirus lockdown. The figures The FTSE 100-listed firm, which has signed up to produce a front-running coronavirus vaccine candidate, said product sales in the three months to 30 June reached $6.05bn. Analysts [...]
Astrazeneca reaches global agreements to produce 2bn coronavirus vaccine doses June 4, 2020 Drugs giant Astrazeneca has made deals that will mean it can deliver 2bn doses of Oxford University’s potential coronavirus vaccine, double the previous number. The pharmaceuticals firm today said it had signed agreements with the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi the Vaccine Alliance, and the Serum Institute of India (SII) to manufacture the [...]
Astrazeneca set to supply potential coronavirus vaccine in September May 21, 2020 Pharmaceuticals giant Astrazeneca has confirmed it is prepared to deliver the first 400m doses of its potential coronavirus vaccine from September. In total, the drugmaker, which is the delivery partner for the University of Oxford, has secured the capacity to manufacture 1bn doses of the treatment over the next two years. Of the doses, 100m [...]
Astrazeneca partners with Oxford University to manufacture coronavirus vaccine April 30, 2020 Drugs giant Astrazeneca has partnered with Oxford University to manufacture its potential Covid-19 vaccine, the firm announced this morning. The vaccine, which is being developed by the Jenner Institute and the Oxford Vaccine Unit, is one of 70 treatments worldwide that is under development to counter the coronavirus disease. Last week the first human trials [...]
Astrazeneca retains guidance after strong first quarter performance April 29, 2020 Pharmaceuticals giant Astrazeneca reported strong revenue and profit growth for the first quarter of 2019 amid the coronavirus disruption. The Anglo-Swedish company beat analyst expectations and maintained its sales and earning guidance for the whole year. Shares in the firm rose over one per cent as markets opened. The figures Revenue increased 16 per cent [...]
Astrazeneca to trial diabetes drug as potential coronavirus treatment April 23, 2020 Pharmaceuticals giant Astrazeneca today announced that it was beginning clinical trials to see if one of its diabetes drugs could be used to tackle coronavirus. The trial will test whether Farxiga, which is used to treat type-2 diabetes, can reduce the risk of serious complications and organ failure in coronavirus patients with existing heart and [...]
Astrazeneca profits slump in final quarter as firm warns of coronavirus hit February 14, 2020 Pharmaceuticals giant Astrazeneca saw profit nearly halve in the fourth quarter as the firm hit a bump in its road to recovery. The FTSE blue chip warned that its 2020 growth would take a hit due to the expected knock-on effect of the coronavirus in China, its second biggest market. Shares in the UK firm [...]
Astrazeneca takes $100m hit on failed heart disease drug tests January 13, 2020 Astrazeneca is in line for a $100m hit after a heart disease drug was shown to be ineffective in treating certain heart conditions in tests. After the disappointing results, the drug manufacturer said it would stop running trials on the drug, known as Epanova. Read more: Astrazeneca beats estimates in strong third quarter It also [...]
Astrazeneca pushes further into China with trio of new projects November 6, 2019 Astrazeneca this morning unveiled three new initiatives to further deepen the UK-based company’s footprint in China. The pharmaceuticals multinational has agreed a partnership with China International Capital Corporation (CICC), one of China’s leading investment banks, to create a $1bn Healthcare Industrial Fund. Read more: AstraZeneca beats estimates in strong third quarter Astrazeneca will be a [...]
Astrazeneca share price hits record high on ‘exceptionally impressive’ trial results September 2, 2019 Shares in Astrazeneca reached a record high today after the company kicked off September with strong results from two drug trials. The company’s share price ticked up as much as 3.6 per cent to 7,583p, as it said drug Brilinta, when taken with aspirin, lowered the risk of heart attacks and strokes in several types [...]